Targeting immune privilege to prevent pathogenic neovascularization

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 7, 2010, Pages 3560-3566

  Roychoudhury, Jayeeta ^a   Herndon, John M ^a   Yin, Jiyi ^a   Apte, Rajendra S ^a   Ferguson, Thomas A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; DRINKING WATER; FAS ANTIGEN; FAS LIGAND; CD11B ANTIGEN; FASL PROTEIN, MOUSE; TNFSF10 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B6 GLD MOUSE; BLINDNESS; C57BL 6 MOUSE; CELL MIGRATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG TARGETING; IMMUNE PRIVILEGE; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; INFLAMMATION; MACROPHAGE; MOUSE; MOUSE STRAIN; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN SECRETION; SUBRETINAL NEOVASCULARIZATION; ANIMAL; BLOOD; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; INJECTION; METABOLISM; ORAL DRUG ADMINISTRATION; VASCULAR ENDOTHELIUM; VITREOUS BODY;

ADMINISTRATION, ORAL; ANIMALS; ANTIGENS, CD11B; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; DOXYCYCLINE; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE EXPRESSION; IMMUNE SYSTEM; INJECTIONS; MICE; MICE, INBRED C57BL; RETINAL PIGMENT EPITHELIUM; TNF-RELATED APOPTOSIS-INDUCING LIGAND; VITREOUS BODY;

EID: 77955904070     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-3890     Document Type: Article

References (40)

1. Apte RS, Richter J, Herndon J, Ferguson TA. Macrophages inhibit neovascularization in a murine model of age-related macular degeneration. PLoS Med. 2006;3:e310.
2. Niederkorn JY. Immune privilege in the anterior chamber of the eye. Crit Rev Immunol. 2002;22:13-46.
3. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270:1189-1192.
4. Lee HO, Herndon JM, Barreiro R, Griffith TS, Ferguson TA. TRAIL: a mechanism of tumor surveillance in an immune privileged site. J Immunol. 2002;169:4739-4744.
5. Ferguson TA, Green DR. Fas-ligand and immune privilege: the eyes have it. Cell Death Differ. 2001;8:771-772.
6. Griffith TS, Yu X, Herndon JM, Green DR, Ferguson TA. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity. 1996;5:7-16.
7. Kezuka T, Streilein JW. Evidence for multiple CD95-CD95 ligand interactions in anteriorchamber-associated immune deviation induced by soluble protein antigen. Immunology. 2000;99:451-457.
8. Stuart PM, Pan F, Plambeck S, Ferguson TA. FasL-Fas interactions regulate neovascularization in the cornea. Invest Ophthalmol Vis Sci. 2003;44:93-98.
9. Barreiro R, Schadlu R, Herndon J, Kaplan HJ, Ferguson TA. The role of Fas-FasL in the development and treatment of ischemic retinopathy. Invest Ophthalmol Vis Sci. 2003;44:1282-1286.
10. Kaplan HJ, Leibole MA, Tezel T, Ferguson TA. Fas ligand (CD95 ligand) controls angiogenesis beneath the retina. Nat Med. 1999; 5:292-297.
11. Volpert OV, Zaichuk T, Zhou W, et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med. 2002;8:349-357.
12. Ferguson TA, Apte RS. Angiogenesis in eye disease: immunity gained or immunity lost? Semin Immunopathol. 2008;30:111-119.
13. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308: 385-389.
14. van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT. Epidemiology of age-related maculopathy: a review. Eur J Epidemiol. 2003;18:845-854.
15. Errami M, Galindo CL, Tassa AT, Dimaio JM, Hill JA, Garner HR. Doxycycline attenuates isoproterenol- and transverse aortic banding-induced cardiac hypertrophy in mice. J Pharmacol Exp Ther. 2008;324:1196-1203.
16. Taylor PR, Martinez-Pomares L, Stacey M, Lin HH, Brown GD, Gordon S. Macrophage receptors and immune recognition. Annu Rev Immunol. 2005;23:901-944.
17. Nakao S, Kuwano T, Tsutsumi-Miyahara C, et al. Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. J Clin Invest. 2005; 115:2979-2991.
18. Espinosa-Heidmann DG, Suner IJ, Hernandez EP, Monroy D, Csaky KG, Cousins SW. Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest Oph-thalmol Vis Sci. 2003;44:3586-3592.
19. Sakurai E, Anand A, Ambati BK, van Rooijen N, Ambati J. Macro-phage depletion inhibits experimental choroidal neovasculariza-tion. Invest Ophthalmol Vis Sci. 2003;44:3578-3585.
20. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308:419-421.
21. Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science. 2005;308:421-424.
22. Hageman GS, Anderson DH, Johnson LV, et al. A common haplo-type in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A. 2005;102:7227-7232.
23. Kelly J, Khan AA, Yin J, Ferguson TA, Apte RS. Senescence regulates macrophage activation and angiogenic fate at sites of tissue injury in mice. J Clin Invest. 2007;117:3421-3426.
24. Fainaru O, Adini I, Benny O, et al. Doxycycline induces membrane expression of VE-cadherin on endothelial cells and prevents vascular hyperpermeability. FASEB J. 2008;22:3728-3735.
25. Rossiter HB, Scadeng M, Tang K, Wagner PD, Breen EC. Doxycy-cline treatment prevents alveolar destruction in VEGF-deficient mouse lung. J Cell Biochem. 2008;104:525-535.
26. Hebda PA, Whaley D, Kim HG, Wells A. Absence of inhibition of cutaneous wound healing in mice by oral doxycycline. Wound Repair Regen. 2003;11:373-379.
27. Stuart PM, Pan F, Yin X, Haskova Z, Plambeck S, Ferguson TA. Effect of metalloprotease inhibitors on corneal allograft survival. Invest Ophthalmol Vis Sci. 2004;45:1169-1173.
28. Yao JS, Chen Y, Zhai W, Xu K, Young WL, Yang GY. Minocycline exerts multiple inhibitory effects on vascular endothelial growth factor-induced smooth muscle cell migration: the role of ERK1/2, PI3K, and matrix metalloproteinases. Circ Res. 2004;95:364-371.
29. Solomon A, Rosenblatt M, Li DQ, et al. Doxycycline inhibition of interleukin-1 in the corneal epithelium. Invest Ophthalmol Vis Sci. 2000;41:2544-2557.
30. Ferguson TA, Griffith TS. A vision of cell death: Fas ligand and immune privilege 10 years later. Immunol Rev. 2006;213:228-238.
31. Ip MS, Scott IU, Brown GC, et al. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology. 2008;115:1837-1846.
32. Stuart PM, Griffith TS, Usui N, Pepose J, Yu X, Ferguson TA. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest. 1997;99:396-402.
33. Niederkorn JY. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat Immunol. 2006;7:354-359.
34. Semkova I, Fauser S, Lappas A, et al. Overexpression of FasL in retinal pigment epithelial cells reduces choroidal neovasculariza-tion. FASEB J. 2006;20:1689-1691.
35. Jorgensen A, Wiencke AK, la Cour M, et al. Human retinal pigment epithelial cell-induced apoptosis in activated T cells. Invest Oph-thalmol Vis Sci. 1998;39:1590-1599.
36. Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity. 2009;30:180-192.
37. Schulte M, Reiss K, Lettau M, et al. ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death. Cell Death Differ. 2007;14:1040-1049.
38. Zuccato E, Blott EJ, Holt O, et al. Sorting of Fas ligand to secretory lysosomes is regulated by mono-ubiquitylation and phosphoryla-tion. J Cell Sci. 2007;120:191-199.
39. Webster GF, Toso SM, Hegemann L. Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin: involvement of protein kinase C. Arch Dermatol. 1994;130:748-752.
40. Hoyt JC, Ballering J, Numanami H, Hayden JM, Robbins RA. Doxy-cycline modulates nitric oxide production in murine lung epithelial cells. J Immunol. 2006;176:567-572.